|
This email is being sent to local health officers, tribal health directors, COVID-19 vaccinators, COVID-19 vaccine stakeholders, HERC coordinators, and key DHS staff.
DHS Supports FDA Approval and Authorization, and CDC Recommendation for new 2023-24 COVID-19 Vaccine Formula
The Wisconsin Department of Health Services (DHS) supports the Centers for Disease Control and Prevention’s (CDC) recommendation that:
-
Everyone ages 5 years and older is recommended to receive 1 dose of a 2023–2024 mRNA COVID-19 vaccine.
-
Children ages 6 months–4 years should complete a multi-dose initial series (2 doses of Moderna or 3 doses of Pfizer-BioNTech mRNA COVID-19 vaccine) with at least one dose of the 2023–2024 COVID-19 vaccine.
More details, including recommendations for people who are moderately or severely immunocompromised will be included in the CDC Interim Clinical Considerations.
Note that the above recommendations are based upon initial information from the CDC and that the CDC Interim Clinical Considerations have not yet been released. Vaccinators should follow the specific CDC clinical guidance once it is published by the CDC.
On September 11, the U.S. Food and Drug Administration (FDA) took action by approving and authorizing for emergency use updated COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death. As part of the FDA’s actions, the bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.
The bivalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States.
FDA’s actions related to updated mRNA vaccines for 2023-2024 manufactured by ModernaTX Inc. and Pfizer Inc. Consistent with the totality of the evidence and input from the FDA’s expert advisors, these vaccines have been updated to include a monovalent (single) component that corresponds to the Omicron variant XBB.1.5.
On September 12, the CDC director endorsed the CDC Advisory Committee on Immunization Practices (ACIP) recommendations.
Read the full bulletin sent on Wednesday, September 13 for more information, including vaccine fact sheets, formulation presentations, and ordering information.
As a reminder, these new vaccines are available to be purchased by providers through distributers or wholesalers. Because the vaccines are no longer purchased by the federal government, WI-DHS will not have a stockpile or inventory. State supplied vaccine is limited to eligible individuals through VFC and BAP
CDC COCA Call: Preparing for the Upcoming Respiratory Virus Season: Recommendations for Influenza, COVID-19, and RSV Vaccines for Older Adults
The CDC is preparing for co-circulating influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) this fall and winter. Vaccines can provide life-saving protection against all three viral respiratory diseases. CDC recommends these vaccines for older adults who are at a higher risk of severe illness from these diseases. Clinicians play a vital role in ensuring that older adults protect themselves by encouraging them to stay up to date on influenza, COVID-19, and RSV vaccinations.
During this COCA Call, CDC presenters will provide updates about the latest recommendations and clinical considerations for administering influenza, COVID-19, and RSV vaccines to adults 60 years and older and discuss resources and communication strategies that may help facilitate older adult vaccination.
If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.
The slide set will be available on the day of the call on the COCA Call webpage under Call Materials.
Registration is not required.
Date: Tuesday, September 19, 2023
Passcode: 493303
DHS September 12 Vaccinator Webinar: Recording and Links
The webinar includes content on commercialization, federal COVID-19 vaccine dose closeout, as well as other important information for vaccinators/providers on the wind down of the federal COVID-19 vaccine program.
Updated COVID-19 Vaccine Training Resources
Pfizer: You can register for COVID-19 Vaccine Training Webinars led by Pfizer Vaccines Medical Affairs. The training includes information on COMIRNATY® (COVID-19 Vaccine, mRNA) and Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula). September sessions are available with more expected to be added in the future. Pfizer also plans to add on-demand training soon.
Moderna: Over the next few weeks, Moderna will host several virtual briefings to review details about the Moderna COVID-19 Vaccine (2023–2024 Formulation), including ACIP recommendations, dosing and administration, storage and handling, and safety and efficacy data. The 15-minute presentations will be followed by a live Q&A.
Understanding the Updated Moderna COVID-19 Vaccine (2023-2024 Formulation)
Novavax: With Novavax not yet authorized for an updated COVID-19 vaccine, the video resources below are for the prior presentation.
|
